Please follow these directions carefully:
Attention: Due to high volume of paperwork, PLEASE do not send us this instruction sheet. We only need the immunization forms.

Accurate and complete immunization information is required for registration at Fordham University. Please make sure all forms have your name, DOB, and Fordham ID number on them. Incomplete information may result in delayed processing of your registration.

Immunization Hotline for Questions: 718-817-0940

Students: Once your health care provider has completed this form, make a copy for your records and return the original to the address listed on this sheet; or you may fax forms to (718) 817-3218; or scan forms to health@fordham.edu. Forms must have a health care provider’s signature, stamp, and license number. Incomplete forms will not be processed.

Health Care Providers: For each section, provide the date of immunization. If documenting illness, measles and mumps must be accompanied by a letter from an MD, PA, or NP. For serologic testing (titers), lab results showing immunity must be attached. Please note the date format of Month/Day/Year (MM/DD/YY). All immunizations must have been received after the first birthday. Forms must have a health care provider’s signature, stamp, and license number. Incomplete forms will not be processed.

SECTION I, II, & III ARE MANDATORY

SECTION IV IS ONLY RECOMMENDED (encouraged if student has a medical condition or is on prescribed medication(s))

NEW YORK STATE VACCINATION LAW 2165 and 2167:

If a student is registered to attend for less than 6 semester hours or 4 credit hours per quarter, the immunization requirements do not apply to that student. If an enrollee at a post-secondary institution was born before 1957, he/she does not have to comply with PHL Section 2165 immunization requirements.

SECTION I. MMR: Two doses are required for entry into Fordham University. This combination vaccine is given because it protects from Measles, Mumps, and Rubella. *MMR was not available in the U.S. before 1/1/1972.*

1. Measles (Rubella): Students born on or after January 1, 1957 must submit proof of immunity to measles. Only ONE of the following is required:
   - The student must submit proof of two doses of live measles vaccine: the first dose given no more than 4 days prior to the student's first birthday and the second at least 28 days after the first dose; or
   - The student must submit serological proof of immunity (titer) to measles. This means the demonstration of measles antibodies through a blood test performed by an approved medical laboratory; or
   - The student must submit a statement from the diagnosing physician, physician assistant or nurse practitioner that the student has had measles disease; or
   - The student must submit proof of honorable discharge from the armed services within 10 years from the date of application to the institution. The proof of honorable discharge shall qualify as a certificate enabling a student to attend the institution pending actual receipt of immunization records from the armed services; or
   - If a student is unable to access his/her immunization record from a health care provider or previous school, documentation that proves the student attended primary or secondary school in the United States after 1980 will be sufficient proof that the student received one dose of live measles vaccine. If this option is used, the second dose of measles vaccine must have been administered within one year of attendance at a post-secondary institution.

2. Mumps: Students born on or after January 1, 1957 must submit proof of immunity to mumps. Only ONE of the following is required:
   - The student must submit proof of two doses of live mumps vaccine given no more than 4 days prior to the student's first birthday; or
   - The student must submit serological proof of immunity (titer) to mumps. This means the demonstration of mumps antibodies through a blood test performed by an approved medical laboratory; or
   - The student must submit a statement from the diagnosing physician, physician assistant, or nurse practitioner that the student has had mumps disease; or
   - The student must submit proof of honorable discharge from the armed services within 10 years from the date of application to the institution. The proof of honorable discharge shall qualify as a certificate enabling a student to attend the institution pending actual receipt of immunization records from the armed services.

3. Rubella (German measles): Students born on or after January 1, 1957 must submit proof of immunity to rubella. Only ONE of the following is required:
   - The student must submit proof of one dose of live rubella vaccine: the first dose given no more than 4 days prior to the student's first birthday; or
   - The student must submit serological proof of immunity (titer) to rubella. This means the demonstration of rubella antibodies through a blood test performed by an approved medical laboratory (Since rubella rashes resemble rashes of other diseases, it is impossible to diagnose reliably on clinical grounds alone. Serological evidence is the only permissible alternative to immunization.); or
- The student must submit proof of honorable discharge from the armed services within 10 years from the date of application to the institution. The proof of honorable discharge shall qualify as a certificate enabling a student to attend the institution pending actual receipt of immunization records from the armed services.

SECTION II. Meningococcal Meningitis:

New York State PHIL. Section 2167 requires post-secondary institutions to distribute information about meningococcal disease and immunization to the students, or parents or guardians of students under the age of 18, accompanied by a response form. The institution is required to maintain appropriate documentation for each student. Acceptable documentation includes any of the following:

- A vaccine record indicating at least 1 dose of meningococcal ACWY vaccine within the last 5 years or a complete 2- or 3-dose series of MenB without a response form; or
- A signed response form with a vaccine record (If a student submits a response form selecting this option, a vaccine record must be attached); or
- A signed response form indicating that the student will obtain meningococcal vaccine within 30 days; or
- A signed response form indicating that the student will not obtain immunization against meningococcal disease.

If the student has not received meningococcal vaccine within the past 5 years, then he/she must submit the signed response form.

Information about Meningococcal Disease: College students, especially freshman living in residence halls, are at a slightly increased risk for contracting meningococcal disease. The bacterial form of this disease can lead to serious complications such as swelling of the brain, corna, and even death within a short period of time. Several vaccines are currently available that will decrease, but not completely eliminate, a person’s risk of acquiring meningococcal meningitis. This element of uncertainty remains because there are five (5) different Serotypes (A, B, C, Y, & W-135). The vaccines, Menactra™ and Menveo™, probably protect against the strains ACWY for 3-5 years, and are extremely safe for use. Menactra™ vaccine is available at the Fordham University Health Services. Also available are the vaccines for Meningitis Serogroup B: Trumenba (3 dose series) and Bexsero (2 dose series). Please see the Meningitis Fact Sheet.

For more specific information about meningococcal meningitis and college student risks, please visit the NYS DOH Website: http://www.health.state.ny.us/nysdoh/immun/mentingococcal/index.htm

SECTION III. Tuberculosis (TB) Risk Factor Screening: All students must complete Part 1- Tuberculosis (TB) Screening Questionnaire. If the student answers YES to any of those questions, Fordham University requires that you receive a Clinical Assessment from your healthcare provider as soon as possible, prior to the start of the semester. Part 2 and Part 3 must be completed by a healthcare provider.

Information about TB Screening: Universal tuberculin or Interferon Gamma Release Assay (IGRA) testing is not recommended in the U.S and other low-incidence countries due to the high rate of false positive results. Tuberculin or IGRA testing is indicated for children/individuals with the following risk factors for TB:

1. History of exposure to anyone with TB
2. Immigration from a country with a high incidence of TB
3. Travel to a high-incidence country where housing was with family members or local resident-not hotels, resorts, etc.
4. Household contact with parents or others who immigrated from a country with a high incidence of TB and tuberculin status unknown (consider testing at ages 1.5,12)
5. Exposure to individuals in the past 5 years who are HIV-infected, homeless, institutionalized, users of illicit drugs, incarcerated (test all groups every 2-3 years
6. HIV infection (test yearly), diabetes mellitus, chronic renal failure, malnutrition, reticuloendothelial disease, other immunodeficiencies or receiving immunosuppressive therapy

We strongly recommend that international students from high risk countries have the IGRA testing completed. Countries with a high incidence of TB (incidence of >20/100,000) are listed at the following link:
http://apps.who.int/gho/data/view.main.57040?lang=en. (Includes most countries of Asia, Africa, Eastern Europe, Central and South America)

If patient/student has a documented positive result to a previous TST (Mantoux) or IGRA, the test should not be repeated. The student will need a chest xray to meet compliance.

SECTION IV. Recommended (not mandatory): Space is provided to record this information.

A. Tetanus-Diphtheria: booster shot within the past 10 years.
B. Hepatitis B Vaccine: It is recommended that all infants, children and adolescents up to the age of 18 receive the Hepatitis B vaccine. It is also recommended for adults who may be at high risk for infection.
C. Hepatitis A Vaccine: It is recommended that all children at 1 year old receive the Hepatitis A vaccine.
Meningococcal Meningitis Fact Sheet

What is meningococcal disease? Meningococcal disease is a severe bacterial infection of the bloodstream or meninges (a thin lining covering the brain and spinal cord) caused by the Neisseria meningitidis germ.

Who gets meningococcal disease? Anyone can get meningococcal disease, but it is more common in infants and children, and those living in crowded conditions (such as college students). Other persons at increased risk include household contacts of those known to have the disease, immunocompromised people, and people traveling to parts of the world where the disease is common.

How is the meningococcus germ spread? It is spread by coming in contact with the nose or throat secretions of an infected person.

What are the symptoms? High fever, headache, vomiting, stiff neck and a rash are symptoms of meningococcal disease. The symptoms may appear 2 to 10 days after exposure, but usually within 5 days. Among people who develop meningococcal disease, 10-15% die, in spite of treatment. Of those who live, permanent brain damage, hearing loss, kidney failure, loss of arms or legs, or chronic nervous system can occur.

What is the treatment for meningococcal disease? Antibiotics are the mainstay of treatment for the meningococcal disease.

Is there a vaccine to prevent meningococcal meningitis? There are two types of meningococcal vaccines available in the US:
• Meningococcal conjugate vaccine (ACWY) - Menactra and Menveo
• Serogroup B Vaccine - Bexsero and Trumenba.

Who should get the meningococcal vaccine? The vaccine is recommended for:
• All 11 to 18 years old;
• All first year college students living in dormitories;
• Some people are at increased risk for meningococcal disease due to having certain medical conditions or taking specific medications, or because of travel, their profession, or a meningococcal disease outbreak.

I had one meningitis vaccine. Do I need a booster dose? Menactra and Menveo require a booster. Immunity with these vaccinations wane after 3-5 years. A booster dose is recommended for students headed to college if it has been more than 5 years since their last dose.

Is the vaccine safe? Meningococcal vaccines are very safe, and they are effective at preventing meningococcal disease. Vaccines, like any medicine, can have side effects. The most common side effects with meningococcal vaccines are mild, like a sore arm, and usually last no more than 1 or 2 days.

FORDHAM UNIVERSITY HEALTH SERVICES
2019-2020

Name: ________________________________ Fordham ID #: ____________________
Cell Phone Number: __________________________ DOB: ________________________ (MM/DD/YYYY)
E-mail: ______________________@fordham.edu Graduating Year: ________________

Please check off those that apply:

___International Student (F-1, J-1) Campus: ___Rose Hill ___Lincoln Center ___Westchester
___Domestic Student Status: ___Undergraduate ___Graduate (incl. GBA) ___Law Student

SECTION I: MMR (Measles, Mumps, Rubella: For ALL students born after 01/01/1957) – 2 Doses

MMR #1: ___/___/____ (on or after 1st birthday) MMR #2: ___/___/____ (after 15 mo. of age or 28 days after 1st dose)

OR: Vaccination dates of 2 Measles, 2 Mumps, and 1 Rubella vaccinations

Measles: ___/___/____ Mumps: ___/___/____ Rubella: ___/___/____

Measles: ___/___/____ Mumps: ___/___/____

OR: Blood Antibody Titer Test (Serological Proof of Immunity must be attached)

Measles: ___/___/____ Mumps: ___/___/____ Rubella: ___/___/____

History of Disease: Any history of contracting the Measles or Mumps disease, please indicate date(s) below.

Measles: ___/___/____ Mumps: ___/___/____

SECTION II: MENINGITIS VACCINE or MENINGITIS WAIVER: Must have vaccine record indicating at least one dose of meningitis ACWY vaccine within the last 5 years OR a complete 2 or 3 dose series of MenB, OR must sign Meningitis Waiver below.

Highly Recommended Meningitis ACWY vaccine(s): Menactra or Menveo within the last 5 years.

Menactra: ___/___/____ Menveo: ___/___/____

Highly Recommended Meningitis Serogroup B vaccines are highly recommended for anyone 16-23 years old to provide short-term protection against most strains of serogroup B meningococcal disease.

Trumenba Dose 1: ___/___/____ Dose 2: ___/___/____ Dose 3: ___/___/____

Bexsero Dose 1: ___/___/____ Dose 2: ___/___/____

Required Meningitis Waiver: A mandatory waiver must be signed if the student does not receive the recommended meningitis vaccines as stated above. This waiver will acknowledge the patient was educated regarding meningococcal risks and refusal of meningococcal vaccination.

I have, or for students under 18, “My child has”:

Read or have had explained to me, the information regarding meningococcal meningitis disease. I understand the risks of not receiving the vaccine. I have decided that:

I (my child) WILL NOT obtain immunization against meningococcal meningitis disease.

Signature: ___________________________ Date: ________________
Section III: Tuberculosis (TB) Screening Questionnaire (to be completed by incoming students)

Part I. Please answer the following questions:

Have you ever had close contact with persons known or suspected to have active TB disease?  
☐ Yes  ☐ No

Were you born in one of the countries or territories listed below that have a high incidence of active TB disease? (If yes, please CIRCLE the country, below)

- Afghanistan
- Algeria
- Angola
- Argentine
- Armenia
- Azerbaijan
- Bangladesh
- Belarus
- Belize
- Benin
- Bhutan
- Bolivia (Plurinational State of)
- Bosnia and Herzegovina
- Botswana
- Brazil
- Brunei Darussalam
- Bulgaria
- Burkina Faso
- Burundi
- Cabo Verde
- Cambodia
- Cameroon
- Central African Republic
- Chad
- China
- China, Hong Kong SAR
- China, Macao SAR
- Colombia
- Comoros

Iran (Islamic Republic of)
Iraq
Kazakhstan
Kenya
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lesotho
Liberia
Libya
Lithuania
Madagascar
Malawi
Malaysia
Mali
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia (Federated States of)
Mongolia
Montenegro
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Nicaragua
Niger
Nigeria
Northern Mariana Islands
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Qatar
Republic of Korea
Republic of Moldova
Romania
Russian Federation
Rwanda
Saint Vincent and the Grenadines
Sao Tome and Principe
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Solomon Islands
Somalia
South Africa
South Sudan
Sri Lanka
Sudan
Suriname
Swaziland
Tajikistan
Thailand
Timor-Leste
Togo
Trinidad and Tobago
Tunisia
Turkmenistan
Tuvalu
Uganda
Ukraine
United Republic of
Tanzania
Uruguay
Uzbekistan
Vanuatu
Venezuela (Bolivarian Republic of)
Viet Nam
Yemen
Zambia
Zimbabwe


Have you had frequent or prolonged visits* to one or more of the countries or territories listed above with a high prevalence of TB disease? (If yes, CHECK the countries or territories, above)  
☐ Yes  ☐ No

Have you been a resident and/or employee of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)?  
☐ Yes  ☐ No

Have you been a volunteer or health care worker who served clients who are at increased risk for active TB disease?  
☐ Yes  ☐ No

Have you ever been a member of any of the following groups that may have an increased incidence of latent *M. tuberculosis* infection or active TB disease: medically underserved, low-income, or abusing drugs or alcohol?  
☐ Yes  ☐ No

If the answer is YES to any of the above questions, Fordham University requires that you receive TB testing as soon as possible, prior to the start of the semester. Have your physician complete the Tuberculosis (TB) Clinical Assessment in Part II with additional testing and/or documentation.

If the answer to all of the above questions is NO, no further testing or further action is required. Both student and provider must sign below. You can go directly to Section IV.

*The significance of the travel exposure should be discussed with a health care provider and evaluated.*

Student Signature: ______________________________ Date: ______________________________

Provider Signature: ______________________________ Date: ______________________________
Part II. Tuberculosis Clinical Assessment by Health Care Provider

Clinicians should review and verify the information in Part I. Students answering YES to any of the questions in Part I are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented. It is strongly recommended that international students from high incidence areas have IGRA testing.

History of a positive TB skin test or IGRA blood test? (If yes, document below)  □ Yes  □ No

History of BCG vaccination? (If yes, consider IGRA if possible.)  □ Yes  □ No

1. TB Symptom Check

Does the student have signs or symptoms of active pulmonary tuberculosis disease?  Yes _____ No _____

If No, proceed to 2 or 3

If yes, check all symptoms that apply: □ Cough (especially if lasting for 3 weeks or longer) with or without sputum production, □ Coughing up blood (hemoptysis), □ Chest pain, □ Loss of appetite, □ Unexplained weight loss, □ Night sweats, □ Fever

If yes, Proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

2. Tuberculin Skin Test (TST)

(TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write “0”). **

Date given: _____/_____/_____  Date read: _____/_____/_____  

Result: ________mm of induration  ** Interpretation: Positive________ Negative________

**Interpretation guidelines: The TST interpretation should be based on mm of induration as well as risk factors.

>5 mm is positive:

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
- Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 mg/d of prednisone for >1 month.)
- HIV-infected persons

>10 mm is positive:

- Recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* amount of time
- Injection drug users
- Mycobacteriology laboratory personnel
- Residents, employees, or volunteers in high-risk congregate settings
- Persons with medical conditions that increase the risk of progression to TB disease including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunooileal bypass and weight loss of at least 10% below ideal body weight.

>15 mm is positive:

- Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.
- * The significance of the travel exposure should be discussed with a health care provider and evaluated.

Date Obtained: ____/_____/____ (specify method) OFT-GIT  T-Spot  Other______

Result: negative_____ positive_____ indeterminate____ borderline_____ (T-spot only)

4. Chest x-ray: Required if TST of IGRA is positive. Please attach a copy of the report (no discs of films)

Date of chest x-ray: ____/_____/______ Result: normal_____ abnormal_____

Part III. Management of Positive TST or IGRA

All students with a positive TST or IGRA with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.

- Infected with HIV
- Recently infected with M. tuberculosis (within the past 2 years)
- History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to /greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
- Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
- Have had a gastrectomy or jejunooileal bypass
- Weigh less than 90% of their ideal body weight
- Cigarette smokers and persons who abuse drugs and/or alcohol

**Populations defined locally as having an increased incidence of disease due to M. tuberculosis, including medically underserved, low-income populations

_______ Student agrees to receive treatment
_______ Student declines treatment at this time

_______________________________________________            _____________________________________
Health Care Professional Signature                                      Date

(____)___________________________________________           (___)_________________________________
Telephone                                                                     Fax

Provider Stamp:
SECTION IV: RECOMMENDED (NOT MANDATORY)

A. Tetanus-Diphtheria (*Immunization booster within last 10 years*):

Date: _____ / _____ / _____
mo. day yr.

B. Hepatitis B Vaccine

Dose 1: _____ / _____ / _____
mo. day yr.

Dose 2: _____ / _____ / _____
mo. day yr.

Dose 3: _____ / _____ / _____
mo. day yr.

C. Hepatitis A Vaccine

Dose 1: _____ / _____ / _____
mo. day yr.

Dose 2: _____ / _____ / _____
mo. day yr.

An official stamp of a doctor’s office, clinic, or health department AND and authorized signature must be provided below.

Name/License # (Office Stamp) ____________________________________________________________________________

Clinician Signature ____________________________________________________________________________

Date ____________________________________________________________________________

Mail/Fax/E-mail Scanned Document

Fordham University Health Services
Attn: Immunizations
441 East Fordham Road, Bronx, NY 10458
Phone: 718-817-0940 Fax: 718-817-3218
Email: health@fordham.edu